NCT03707340View on ClinicalTrials.gov

A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

October 14, 2025

Study Completion Date

October 14, 2025

Conditions
Breast CancerHyposexual Desire Disorder
Interventions
DRUG

Flibanserin Pill

Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24-36 weeks and followed for a total of 52 weeks.

Trial Locations (7)

10021

Memorial Sloan - Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

06850

Norwalk Hospital, Norwalk

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03707340 - A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | Biotech Hunter | Biotech Hunter